Otsuka takes license for CART therapy targeting active integrin ß7

Otsuka Pharmaceutical has entered into a worldwide exclusive license agreement with Osaka University for for receptor T cell (CART) therapy (MMG 49 CAR-T cell therapy). MMG49 is a chimeric antigen targeted to active integrin β7 found in multiple myeloma.

Otsuka Pharma news release, August 21, 2018

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny